H2 blockers in the prevention of paclitaxel-related hypersensitivity reaction
- PMID: 35818100
- DOI: 10.25259/NMJI_489_21
H2 blockers in the prevention of paclitaxel-related hypersensitivity reaction
Comment on
-
The added value of H2 antagonists in premedication regimens during paclitaxel treatment.Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.
References
-
- Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP,. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol. 1987; 5:1232-9
-
- Rowinsky EK, Donehower RC,. Paclitaxel (taxol). N Engl J Med. 1995; 332: 1004-14
-
- Slimano F, Coliat P, Perotin JM, Vella-Boucaud J, Mongaret C, Bouché O,. Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?. Support Care Cancer. 2016; 24:4475-7
-
- Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PM, et al. The added value of H2 antagonists in premedication regimens during paclitaxel treatment. Br J Cancer. 2021; 124:1647-52
-
- Aouam K, Bouida W, Ben Fredj N, Chaabane A, Boubaker H, Boukef R, et al. Severe ranitidine-induced anaphylaxis: A case report and literature review. J Clin Pharm Ther. 2012; 37:494-6
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical